RTI SURGICAL, INC. (NASDAQ:RTIX) Files An 8-K Results of Operations and Financial Condition

13

RTI SURGICAL, INC. (NASDAQ:RTIX) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

On August8, 2017, RTI Surgical, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June30, 2017. A copy of this press release is furnished herewith as Exhibit 99.1.

The information furnished herewith to Item 2.02 of this Current Report, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.

Item 2.02. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release issued by the Company dated August8, 2017.


RTI SURGICAL, INC. Exhibit
EX-99.1 2 d439186dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 For more information,…
To view the full exhibit click here

About RTI SURGICAL, INC. (NASDAQ:RTIX)

RTI Surgical, Inc. is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company’s business primarily consists of six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties. It processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing BIOCLEANSE, TUTOPLAST and CANCELLE SP sterilization processes, and manufactures metal and synthetic implants for distribution to hospitals and surgeons. The Company distributes its implants and services in approximately 50 states and in over 45 countries across the world.

An ad to help with our costs